Evaluation of a Quadrivalent Measles, Mumps, Rubella and Varicella Vaccine in Healthy Children
- 1 August 2005
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in The Pediatric Infectious Disease Journal
- Vol. 24 (8), 665-669
- https://doi.org/10.1097/01.inf.0000172902.25009.a1
Abstract
A quadrivalent measles, mumps, rubella and varicella vaccine would facilitate universal immunization against all 4 diseases, improve compliance and immunization rates and decrease the number of injections given to children and visits to physicians' offices. To evaluate 1- and 2-dose regimens of a combined measles, mumps, rubella and varicella vaccine (ProQuad, referred to as MMRV) manufactured with a varicella component of increased potency. In this partially blind, multicenter study, 480 healthy 12- to 23-month-old children were randomized to receive either MMRV and placebo or M-M-R®II and VARIVAX. Injections were given concomitantly at separate sites. Subjects randomized to receive MMRV and placebo received a second dose of MMRV 90 days later. Subjects were followed for 42 days after each vaccination for adverse experiences. Immunogenicity was evaluated 6 weeks after each vaccination. Measles-like rash and fever during days 5–12 were more common after the first dose of MMRV (rash, 5.9%; fever, 27.7%) than after M-M-R®II and VARIVAX (rash, 1.9%; fever, 18.7%). The incidence of other adverse events were similar between groups. Response rates were >90% to all vaccine components in both groups. Geometric mean titers to measles and mumps were significantly higher after 1 dose of MMRV than after administration of M-M-R®II and VARIVAX. The second dose of MMRV elicited slight to moderate increases in measles, mumps and rubella antibody titers and a substantial increase in varicella antibody titer (from 13.0 to 588.1 glycoprotein antigen-based enzyme-linked immunosorbent assay units/mL). A 1- or 2-dose regimen of MMRV is generally well-tolerated when administered to 12- to 23-month-old children and has a safety and immunogenicity profile similar to that of M-M-R®II and VARIVAX administered concomitantly.Keywords
This publication has 11 references indexed in Scilit:
- Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infectionThe Pediatric Infectious Disease Journal, 2002
- Varicella Vaccine UpdatePediatrics, 2000
- Measles, Mumps, Rubella, and Varicella Combination Vaccine: Safety and Immunogenicity Alone and in Combination with Other Vaccines Given to ChildrenClinical Infectious Diseases, 1997
- Safety and Immunogenicity of a Combined Live Attenuated Measles, Mumps, Rubella, and Varicella Vaccine (MMRIIV) in Healthy ChildrenThe Journal of Infectious Diseases, 1996
- Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy childrenThe Pediatric Infectious Disease Journal, 1996
- Modified cases of chickenpox after varicella vaccinationThe Pediatric Infectious Disease Journal, 1992
- Antibody assays suitable for assessing immune responses to live varicella vaccineVaccine, 1991
- Sensitive enzyme‐linked immunosorbent assay for antibody to varicella‐zoster virus using purified VZV glycoprotein antigenJournal of Medical Virology, 1990
- A sharper Bonferroni procedure for multiple tests of significanceBiometrika, 1988
- Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodiesJournal of Virological Methods, 1986